Results 81 to 90 of about 260,030 (390)
Journal of Current Oncology and Medical Sciences, 2023 Introduction: Colorectal cancer (CRC) is the third common cancer among human and the fourth common reason of mortalities caused by cancers around the world.
Hamid Saeidi Saedi +3 more
doaj
Theranostics, 2020 Background and Purpose: RAS mutations limit the effectiveness of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in combination with chemotherapy for metastatic colorectal cancer (mCRC) patients.
Peng Chen +27 more
semanticscholar +1 more source
Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. [PDF]
, 2012 Pancreatic duct glands (PDGs) have been hypothesized to give rise to pancreatic intraepithelial neoplasia (PanIN). Treatment with the glucagon-like peptide (GLP)-1 analog, exendin-4, for 12 weeks induced the expansion of PDGs with mucinous metaplasia and
Butler, Peter C +5 more
core +1 more source
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Lung Cancer: Targets and Therapy, 2022 Danielle Brazel,1 Zhaohui Arter,1 Misako Nagasaka1– 3 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3St.
Brazel D, Arter Z, Nagasaka M
doaj
JOP : Journal of the pancreas, 2014 Pancreatic cancer is one of the most feared malignancies. The most common form of pancreatic cancer is adenocarcinoma arising from the ductal epithelium. KRAS is the most common oncogene that has been found to be mutated. However, targeting KRAS directly has been difficult.
Muhammad Wasif Saif, Archana Agarwal
openaire +3 more sources
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
FDA Approval Summary: Sotorasib for KRAS G12C Mutated Metastatic NSCLC.
Clinical Cancer Research, 2021 On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib (Lumakras, Amgen) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma proto-oncogene (KRAS) G12C ...
Erica C Nakajima +15 more
semanticscholar +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
Study of KRAS-Related miRNA Expression in Colorectal Cancer
Cancer Management and Research, 2022 Xiaobing Wu,1 Zhifa Li,1 Nanqi Huang,1 Xiaodan Li,2 Rong Chen1 1Gastrointestinal Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China; 2Blood Transfusion Department, The Third Affiliated Hospital ...
Wu X, Li Z, Huang N, Li X, Chen R
doaj
The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali
Indonesian Journal of Biotechnology, 2022 Mutations in the KRAS (Kirsten rat sarcoma viral oncogene homolog gene) and BRAF (v‐Raf murine sarcoma viral oncogene homolog B1) gene play a significant role in primary resistance to colorectal cancer therapy.
Ayu Dewi Ni Nyoman +4 more
doaj +1 more source